BioSkryb
Business Services · North Carolina, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
701 W Main St Ste 200, Durham, North Car...Phone Number
(919) 370-0841Website
www.bioskryb.comRevenue
$16.9 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About BioSkryb
BioSkryb Genomics is a venture-backed developer of genomic amplification technologies based in Durham, North Carolina. The Company's proprietary Primary Template-directed Amplification (PTA) system delivers reproducible, high coverage breadth, and uniformity for various low or ultra-low input sequencing applications. BioSkryb's solutions support sequencing library generation produced from limiting samples that have undergone whole genome amplification, resulting in the highest quality genetic analyses available today.Explore more
BioSkryb Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is BioSkryb your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
BioSkryb, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if BioSkryb had a recent Job posting/layoffs
Product Launch: Get notified when BioSkryb launches new products
Funding: Get notified immidiatlly once BioSkryb has new funding data
Earning: See what the market has to say on BioSkryb recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if BioSkryb has recently received funding, and reach out quickly before it becomes old news!
Check out if BioSkryb is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at BioSkryb
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to BioSkryb
Compare insights from companies similar to BioSkryb, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
BioSkryb is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
BioSkryb is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about BioSkryb.
BioSkryb financials insights
Gather financial insights about BioSkryb, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Angel/Seed
$11.5M
BioSkryb Tech Stack
A closer look at the technologies used by BioSkryb
Most Recent Scoops
Person-Based
Person-Based
Person-Based
Open Position
Open Position
BioSkryb News & Media
BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours
DURHAM, N.C. & MÄNNEDORF, Switzerland--(BUSINESS WIRE)--BioSkryb Genomics and Tecan Group (SIX Swiss Exchange: TECN), today introduced a high-throughput single-cell workflow, combining BioSkryb’s 384-well format of the ResolveOME™ Whole Genome and Transcriptome Single-Cell Core Kit with the Uno Single Cell Dispenser™, provided by Tecan. The integrated solution enables parallel high-resolution analysis of hundreds to thousands of individual cells, addressing growing demand for scalable, multiomiBioSkryb Genomics and Ultima Genomics Launch Collaborative Grant Program to Advance Oncology Research
DURHAM, N.C. & FREMONT, Calif.--(BUSINESS WIRE)--BioSkryb Genomics & Ultima Genomics launched a joint grant program to help researchers focused on emerging areas of oncology with multi-omic platformsBioSkryb Genomics Launches ResolveSEQ MRD: A Next-Generation Measurable Residual Disease (MRD) Discovery Solution
DURHAM, N.C.--(BUSINESS WIRE)--BioSkryb launches ResolveSEQ MRD, an innovative service offering designed to empower further classification and characterization of MRD cells.BioSkryb Genomics Partners with the Human Cell Atlas to Advance Access to the Next Generation of Single-Cell Technology
DURHAM, N.C.--(BUSINESS WIRE)--BioSkryb partnered with the Human Cell Atlas to increase access to BioSkryb’s industry-leading single-cell multiomics technology
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding BioSkryb
Sign Up For FreeTo access detailed company insights
BioSkryb Genomics is a venture-backed developer of genomic amplification technologies based in Durham, North Carolina. The Company's proprietary Primary Template-directed Amplification (PTA) system delivers reproducible, high coverage breadth, and uniformity for various low or ultra-low input sequencing applications. BioSkryb's solutions support se... Read More
